<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113035</url>
  </required_header>
  <id_info>
    <org_study_id>AGLU02905</org_study_id>
    <nct_id>NCT00113035</nct_id>
  </id_info>
  <brief_title>Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease</brief_title>
  <official_title>Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a&#xD;
      critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the&#xD;
      body's cells to break down glycogen (a stored form of sugar) within specialized structures&#xD;
      called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates&#xD;
      and is stored in various tissues, especially heart and skeletal muscle, which prevents their&#xD;
      normal function. The primary objective of this study is to identify potential candidates for&#xD;
      future clinical studies in Pompe disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment>60</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>Patients with late onset Pompe Disease</arm_group_label>
  </arm_group>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must provide written informed consent prior to any study-related procedures being&#xD;
             performed&#xD;
&#xD;
          -  Clinical presentation consistent with late-onset Pompe disease, or a current clinical&#xD;
             diagnosis of late-onset Pompe disease&#xD;
&#xD;
          -  Must be greater than or equal to 8 years of age&#xD;
&#xD;
          -  Must be able to ambulate (use of assistive devices, such as a walker, cane or&#xD;
             crutches, is permitted)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requires the use of invasive ventilatory support&#xD;
&#xD;
          -  Requires the use of noninvasive ventilatory support while awake and in an upright&#xD;
             position&#xD;
&#xD;
          -  Use of any investigational product within 30 days prior to study enrollment&#xD;
&#xD;
          -  Unwillingness to comply with protocol requirements&#xD;
&#xD;
          -  Has clinically significant organic disease, unstable medical condition, serious or&#xD;
             intercurrent illness&#xD;
&#xD;
          -  Is pregnant or lactating&#xD;
&#xD;
          -  Has participated in the Prospective Observational Study in Patients with Late-Onset&#xD;
             Pompe Disease (AGLU02303, &quot;LOPOS&quot;)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tower Hematology/Oncology Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>June 3, 2005</study_first_submitted>
  <study_first_submitted_qc>June 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2005</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <keyword>Glycogen Storage Disease Type II</keyword>
  <keyword>GSD-II</keyword>
  <keyword>Pompe Disease</keyword>
  <keyword>Pompe Disease (Late-Onset)</keyword>
  <keyword>Glycogen Storage Disease Type II (GSD-II)</keyword>
  <keyword>Acid Maltase Deficiency</keyword>
  <keyword>Glycogenosis 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

